1,772 results match your criteria Climacteric[Journal]


Identification of the first homozygous POLG mutation causing non-syndromic ovarian dysfunction.

Climacteric 2018 Jul 11:1-5. Epub 2018 Jul 11.

a Department of Obstetrics and Gynecology , Reproductive Medicine Center, The First Affiliated Hospital of Anhui Medical University , Hefei , China.

Objective: To investigate the genetic cause of non-syndromic ovarian dysfunction in a patient from a consanguineous family.

Methods: This study examined a patient with irregular menstrual cycles and abnormal oocytes. The patient had undergone irregular hormone replacement therapy over 3 years to adjust the menstrual cycle and improve ovarian function. Read More

View Article
July 2018
3 Reads

Progesterone.

Authors:
James H Pickar

Climacteric 2018 Aug;21(4):305

View Article

Menopause - a new beginning.

Authors:
Susan R Davis

Climacteric 2018 Aug;21(4):306-307

a President, International Menopause Society.

View Article

Sexual well-being after menopause: An International Menopause Society White Paper.

Climacteric 2018 Jul 10:1-13. Epub 2018 Jul 10.

j Menopause Unit , Mount Sinai Hospital , Toronto , Canada.

Sexual well-being frequently declines following the menopause transition and can be associated with significant personal and relationship distress. This distress is the hallmark of female sexual dysfunction (FSD). FSD is highly prevalent in postmenopausal women. Read More

View Article

Progesterone for the prevention and treatment of osteoporosis in women.

Authors:
J C Prior

Climacteric 2018 Aug 2;21(4):366-374. Epub 2018 Jul 2.

a Centre for Menstrual Cycle and Ovulation Research, Department of Medicine, Division of Endocrinology , University of British Columbia , Vancouver , BC , Canada.

Estradiol (E2) is women's dominant 'bone hormone' since it is essential for development of adolescent peak bone mineral density (BMD) and physiological levels prevent the rapid (3-week) bone resorption that causes most adult BMD loss. However, deceasing E2 levels trigger bone resorption/loss. Progesterone (P4) is E2's physiological partner, collaborating with E2 in every cell/tissue; its bone 'job' is to increase P4-receptor-mediated, slow (3-4 months) osteoblastic new bone formation. Read More

View Article

Progesterone for treatment of symptomatic menopausal women.

Authors:
J C Prior

Climacteric 2018 Aug 2;21(4):358-365. Epub 2018 Jul 2.

a Centre for Menstrual Cycle and Ovulation Research, Endocrinology and Metabolism , University of British Columbia , Vancouver , BC , Canada.

This review's purpose is to highlight evidence that oral micronized progesterone (progesterone) is effective for hot flushes and night sweats (vasomotor symptoms, VMS), improves sleep and is likely safe in menopausal women (who are more than 1 year since last menstruation). Methods include randomized controlled clinical trials (RCT) supplemented with basic science, population and observational data as needed. The barrier to use of progesterone is lack of awareness that safety concerns with estrogen-including 'menopausal hormone therapy' (MHT) are not applicable to progesterone. Read More

View Article

Health-related quality of life and its associated factors in Chinese middle-aged women.

Climacteric 2018 Jun 1:1-8. Epub 2018 Jun 1.

a Department of Gynecology, Women's Hospital, School of Medicine , Zhejiang University , Hangzhou , People's Republic of China.

Objective: The aim of this study was to compare health-related quality of life (HRQOL) by menopausal stage and investigate its associated factors in middle-aged Chinese women.

Method: This was a cross-sectional, community-based study involving 868 participants aged 40-60 years in Gongshu District, Hangzhou, Zhejiang, PR China. HRQOL was assessed by the Short-Form Health Survey (SF-36). Read More

View Article
June 2018
1 Read

Progesterone, progestins and the breast in menopause treatment.

Climacteric 2018 Aug 1;21(4):326-332. Epub 2018 Jun 1.

a Unité de Gynécologie Endocrinienne, Université Paris Descartes Hôpitaux, Universitaires Port Royal-Cochin , Paris , France.

Breast cancer is the main risk associated with menopause hormone therapy (MHT). It is a hormone-dependent cancer. In postmenopausal women, about 80% of cases are estradiol receptor-positive. Read More

View Article
August 2018
5 Reads

Progesterone and human cognition.

Authors:
V W Henderson

Climacteric 2018 Aug 1;21(4):333-340. Epub 2018 Jun 1.

a Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences , Stanford University , Stanford , CA , USA.

Progesterone is a neurosteroid and a neuroactive steroid, produced primarily by the corpus luteum and the placenta. In some animal models, progesterone affects cognitive performance, and its potential role in human cognition is especially germane to women. This role can be investigated through associations between peripheral concentrations of progesterone in blood or saliva and neuropsychological test results, through differences in cognitive profiles between women using menopausal hormone therapy with and without a progestogen, and through clinical trials. Read More

View Article
August 2018
1 Read

The history of natural progesterone, the never-ending story.

Authors:
P Piette

Climacteric 2018 Aug 28;21(4):308-314. Epub 2018 May 28.

a Consultant at Besins Healthcare Global , Department of R & D, Scientific & Medical Affairs , Brussels , Belgium.

The term progesterone should only be used for the natural hormone produced by the ovaries or included in a registered drug. The modern history of progesterone begins with the first book-length description of the female reproductive system including the corpus luteum and later with the Nobel Prize winner, Adolf Butenandt who took a crucial step when he succeeded in converting pregnanediol into a chemically pure form of progesterone, the corpus luteum hormone. The deficient production of progesterone was shown first to be the cause of the luteal-phase deficiency responsible for infertility and early pregnancy loss due to inadequate secretory transformation of the endometrium. Read More

View Article
August 2018
2 Reads

Non-clinical studies of progesterone.

Authors:
R Sitruk-Ware

Climacteric 2018 Aug 23;21(4):315-320. Epub 2018 May 23.

a Center for Biomedical Research , Population Council , New York , NY , USA.

Progesterone is a steroid hormone that is essential for the regulation of reproductive function. Progesterone has been approved for several indications including the treatment of anovulatory menstrual cycles, assisted reproductive technology, contraception during lactation and, when combined with estrogen, for the prevention of endometrial hyperplasia in postmenopausal hormonal therapy. In addition to its role in reproduction, progesterone regulates a number of biologically distinct processes in other tissues, particularly in the nervous system. Read More

View Article
August 2018
1 Read

Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America.

Climacteric 2018 Aug 9;21(4):397-403. Epub 2018 May 9.

g Palacios Institute of Women's Health , Madrid , Spain.

Objective: To investigate awareness in Latin America, knowledge of postmenopausal vaginal atrophy was evaluated in a sample of women from this region.

Methods: A total of 2509 postmenopausal women aged 55-65 years, resident in Argentina, Brazil, Chile, Colombia and Mexico, completed a structured online questionnaire.

Results: Over half the surveyed population (57%) reported experiencing symptoms of vaginal atrophy. Read More

View Article
August 2018
2 Reads

Ovarian aging: an ongoing prospective community-based cohort study in middle-aged Chinese women.

Climacteric 2018 Aug 9;21(4):404-410. Epub 2018 May 9.

a Department of Obstetrics and Gynecology , Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science , Beijing , People's Republic of China.

Purpose: This study described the design and development of a cohort study established to investigate the ovarian aging process and its impact on women's health.

Methods: A community-based prospective cohort study of middle-aged Chinese women was initiated in 2005 and is ongoing. Sociodemographic characteristics, menstrual calendars, and medical histories were recorded at baseline and at annual follow-ups. Read More

View Article
August 2018
2 Reads

Endometrial pathology in recurrent postmenopausal bleeding: observational study of 385 women.

Climacteric 2018 Aug 9;21(4):391-396. Epub 2018 May 9.

a University of Birmingham , Birmingham , UK.

Objectives: Women with recurrent postmenopausal bleeding (PMB) are considered as being at higher risk for endometrial hyperplasia and cancer, and guidelines suggest offering hysterectomy in unexplained cases with repeated negative investigations. This study aims to determine the prevalence of endometrial pathology in women referred with recurrent PMB to help inform clinical practice.

Methods: This was an observational study of prospectively collected data over a 5-year period, including 1902 women referred to the PMB clinic. Read More

View Article
August 2018
3 Reads
2.26 Impact Factor

The prevalence and determinants of genitourinary syndrome of menopause in Chinese mid-life women: a single-center study.

Climacteric 2018 May 8:1-5. Epub 2018 May 8.

a Department of Gynecology & Obstetrics , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , China.

Objective: This study aimed to explore the prevalence and determinants of genitourinary syndrome of menopause (GSM) in Chinese mid-life women.

Methods: A cross-sectional single-center study was performed among 40-65-year-old women who participated in physical examinations at Shanghai Jiao Tong University Affiliated Sixth People's Hospital from December 2015 to December 2016. The participating women were questioned about their genitourinary symptoms, and the relationships between these symptoms and the women's demographic characteristics were evaluated. Read More

View Article
May 2018
1 Read

History of a brief time: reflections of the first female President.

Authors:
Mary Ann Lumsden

Climacteric 2018 Jun;21(3):202-203

a President of the International Menopause Society, School of Medicine , University of Glasgow, Glasgow Royal Infirmary , Glasgow , UK.

View Article
June 2018
1 Read

Pelvic floor muscle function and EMG in nulliparous women of different ages: a cross-sectional study.

Climacteric 2018 Apr 11:1-5. Epub 2018 Apr 11.

a Physical Therapy Department , Federal University of São Carlos , São Carlos , São Paulo , Brazil.

Background: Although aging is considered a risk factor for pelvic floor muscle dysfunction (PFMD), the effect of aging on the function of the pelvic floor muscles (PFM) remains unclear.

Objective: To compare PFM function and activity in nulliparous women in different age groups.

Methods: This was a cross-sectional study in which 70 women with ages between 18 and 69 years were divided into five age groups for evaluation. Read More

View Article
April 2018
2 Reads

Evidence on the use of progesterone in menopausal hormone therapy.

Authors:
S Mirkin

Climacteric 2018 Aug 9;21(4):346-354. Epub 2018 Apr 9.

a TherapeuticsMD , Boca Raton , FL , USA.

A need exists for a regulatory agency-approved hormone therapy (HT) with naturally occurring hormones combining progesterone (P4) and estradiol (E2), since no single product contains both endogenous hormones. Many women choose HT with P4 and millions of women around the world are using unapproved, poorly regulated compounded HT. The use of natural P4 in HT results, for the most part, in favorable outcomes without deleterious effects, as shown in clinical studies of postmenopausal women. Read More

View Article
August 2018
2 Reads

Bowel cancer screening for women at midlife.

Authors:
I Olver

Climacteric 2018 Jun 3;21(3):243-248. Epub 2018 Apr 3.

a Sansom Institute for Health Research , University of South Australia , Adelaide , Australia.

In Australia one in 15 women will be diagnosed with colorectal cancer in their lifetime because of the high incidences of lifestyle risk factors. The risk could be reduced by taking aspirin. Evidence-based Clinical Practice Guidelines for the prevention, early detection and management of colorectal cancer produced by Cancer Council Australia and approved by the National Health and Medical Research Council recommended that 'population screening in Australia, directed at those at average risk of colorectal cancer and without relevant symptoms, is immunochemical fecal occult blood testing every 2 years, starting at age 50 years and continuing to age 74 years. Read More

View Article
June 2018
2 Reads

Postmenopausal endometriosis: drawing a clearer clinical picture.

Climacteric 2018 Jun 3;21(3):249-255. Epub 2018 Apr 3.

a Section of Reproductive Medicine, Department of Obstetrics and Gynecology , St. Luke's Medical Center-Quezon City , Quezon City , Philippines.

This review aims to draw a clearer clinical picture of postmenopausal endometriosis. Based on limited literature, postmenopausal endometriosis emerges as an infrequent entity but with a clinical picture significantly unlike that of premenopausal endometriosis. In contrast to the premenopausal disease, postmenopausal endometriosis occurs in a state of ovarian estrogen deficiency, appears to have a greater predisposition to malignant change, may have a greater tendency to spread to extragonadal organs and develop into constrictive and/or obstructive lesions, and is preferably treated surgically. Read More

View Article
June 2018
2 Reads

An unusual hazard of menopause in the workplace: a case report.

Climacteric 2018 Jun 3;21(3):303-304. Epub 2018 Apr 3.

b Immunology Private Practice , Nedlands , Australia.

Untreated vasomotor symptoms of the menopause can have a major impact on women at work. Recent recommendations advocate modification of the working environment, including adequate air-conditioning, to help relieve these symptoms. However, this may cause discomfort for work colleagues. Read More

View Article
June 2018
2 Reads

Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy.

Authors:
A Gompel

Climacteric 2018 Aug 27;21(4):321-325. Epub 2018 Mar 27.

a Unité de Gynécologie Endocrinienne , Université Paris Descartes, Hôpitaux Universitaires Port Royal-Cochin , Paris , France.

It is well established that unopposed estrogen for hormone therapy in postmenopausal women (MHT) induces a dose-related stimulation of the endometrium associated with an increased risk of hyperplasia and endometrial cancer. Progesterone acts physiologically to counteract the proliferative effects of estradiol during the menstrual cycle. In MHT, progestogens protect the endometrium against the proliferative effects of estrogens in women with a uterus. Read More

View Article
August 2018
3 Reads

Vaginal progesterone and the vaginal first-pass effect.

Authors:
M P Warren

Climacteric 2018 Aug 27;21(4):355-357. Epub 2018 Mar 27.

a Department of Endocrinology , Columbia University Medical Center , New York , NY , USA.

Vaginal progesterone is an effective alternative to systemic administration by oral or intramuscular use. The first-pass effect is reviewed, as are the most common uses for this route of delivery. This includes use in hormone replacement therapy, luteal support particularly in assisted reproduction, and avoidance of side-effects of oral progestins and progesterone. Read More

View Article
August 2018
2 Reads

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis.

Authors:
P-Y Scarabin

Climacteric 2018 Aug 23;21(4):341-345. Epub 2018 Mar 23.

a Université Paris-Saclay, Université Paris-Sud, UVSQ, Centre de Recherche en Epidémiologie et Santé des Populations , INSERM UMRS1018 Villejuif , France.

Postmenopausal hormone therapy (HT) is a modifiable risk factor for venous thromboembolism (VTE). While the route of estrogen administration is now well recognized as an important determinant of VTE risk, there is also increasing evidence that progestogens may modulate the estrogen-related VTE risk. This review updates previous meta-analyses of VTE risk in HT users, focusing on the route of estrogen administration, hormonal regimen and progestogen type. Read More

View Article
August 2018
4 Reads

Cervical screening in HPV-vaccinated populations.

Authors:
K Canfell

Climacteric 2018 Jun 22;21(3):227-234. Epub 2018 Mar 22.

a Cancer Research Division , Cancer Council NSW , Sydney , NSW , Australia.

Cervical screening with cytology has been the basis for substantial reductions in cervical cancer incidence and mortality in most high-income countries over the last few decades. More recently, there have been two key, parallel developments which have prompted a major re-consideration of cervical screening. The first is the emergence of evidence on the improved sensitivity of human papillomavirus (HPV) DNA testing compared to cytology, and the second is the large-scale deployment of prophylactic vaccination against HPV. Read More

View Article
June 2018
2 Reads

Progestogens and pregnancy loss.

Authors:
H J A Carp

Climacteric 2018 Aug 22;21(4):380-384. Epub 2018 Mar 22.

a Department of Obstetrics & Gynecology , Sheba Medical Center , Tel Hashomer , Israel.

Progestational agents are often prescribed to prevent pregnancy loss. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. Progestogens have therefore been used at all stages of pregnancy including luteal-phase support prior to pregnancy, threatened miscarriage, recurrent miscarriage, and to prevent preterm labor. Read More

View Article
August 2018
3 Reads

The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.

Climacteric 2018 Jun 19;21(3):286-291. Epub 2018 Mar 19.

f Imperial College London , London , UK.

Objectives: The primary objective of the European Vulvovaginal Epidemiological Survey (EVES) was to assess, at a country level, the prevalence of postmenopausal women with vulvovaginal atrophy (VVA) confirmed by gynecological clinical assessment among all postmenopausal women attending menopause centers.

Method: Women aged 45-75 years old with their last menstrual period more than 12 months before and who attended menopause or gynecology centers were included. If they had at least one VVA symptom, women filled a number of questionnaires including the EuroQoL-EQ-5D3L and Day-to-Day Impact of Vaginal Aging (DIVA). Read More

View Article
June 2018
5 Reads

Endothelial dysfunction and menopause: is exercise an effective countermeasure?

Climacteric 2018 Jun 15;21(3):267-275. Epub 2018 Mar 15.

b Department of Kinesiology , University of Massachusetts Amherst , Amherst , MA , USA.

Cardiovascular disease is the leading cause of death in women. There is a dramatic rise in risk factors for cardiovascular disease during the menopausal transition that is independent of aging. Endothelial dysfunction is an early hallmark of developing cardiovascular disease and has been shown to increase across the stages of menopause. Read More

View Article
June 2018
2 Reads

Influence of hormone therapy or C. foetida extract on breast tenderness in postmenopausal women.

Climacteric 2018 Jun 15;21(3):292-297. Epub 2018 Mar 15.

a Department of Obstetrics and Gynecology , Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Beijing , China.

Objective: To evaluate the prevalence of breast tenderness in a population treated with menopausal hormone therapy (MHT) or Cimicifuga foetida extract.

Methods: A prospective, randomized, controlled trial was conducted. Ninety-six postmenopausal women were randomly assigned to three groups: group A, 1 mg estradiol valerate daily plus 4 mg medroxyprogesterone acetate (MPA), days 19-30; group B, 1 mg estradiol valerate daily plus 100 mg micronized progesterone (MP), days 19-30; group C, 100 mg C. Read More

View Article
June 2018
2 Reads

Menopausal hormone therapy: a better and safer future.

Authors:
D A Davey

Climacteric 2018 Mar 11:1-8. Epub 2018 Mar 11.

a Faculty of Health Sciences , University of Cape Town , Western Cape , South Africa.

Major advances in menopause hormone therapy (MHT) hold promise in the future of better and safer care for women at and after the menopause. The principal advances are: (1) the critical window or 'window of opportunity' in the 10 years or so after the menopause, during which the benefits of MHT in healthy women exceed any risks; (2) use of transdermal instead of oral administration of estrogen to reduce the risk of venous thromboembolism; (c) investigation of the use of oral micronized progesterone (MP) and vaginal MP to prevent endometrial hyperplasia and carcinoma without any increased risk of breast cancer and venous thromboembolism in postmenopausal women receiving estrogens; vaginal MP prevents endometrial proliferation in the short term but the long-term effects in MHT remain to be established; (4) investigation into the use of intrauterine levonorgestrel-releasing devices (LNG-IUDs), which are an attractive form of MHT in perimenopausal women, providing contraception and reducing uterine bleeding, although the risk of breast cancer with LNG-IUDs requires clarification. Women in the future can look forward to a symptom-free menopause and to safer and more beneficial MHT. Read More

View Article
March 2018
3 Reads

Migraine, hormones and the menopausal transition.

Climacteric 2018 Jun 9;21(3):256-266. Epub 2018 Mar 9.

c Department of Gynecology , Université Paris Descartes, HUPC , Paris , France.

Migraine is a common, disabling and incapacitating headache disorder that may be triggered by many factors, such as hormones especially during the perimenopausal period, where large alterations in estradiol levels can occur. The evidence implies that hormonal fluctuations are one of the important triggers of migraine. During reproductive life and during hormonal contraception, the course of migraine can be impacted. Read More

View Article
June 2018
3 Reads

Carotid intima-media thickness and osteoporosis in postmenopausal women: a cross-sectional study.

Climacteric 2018 Jun 9;21(3):280-285. Epub 2018 Mar 9.

c Department of Orthopaedics, Faculty of Medicine , Khon Kaen University , Khon Kaen , Thailand.

Objectives: To explore the difference in carotid intima-media thickness (CIMT) between postmenopausal women with and without osteoporosis and the risk of elevated CIMT and plaque presentation.

Method: A cross-sectional study was conducted including 46 postmenopausal women with osteoporosis and 45 non-osteoporotic postmenopausal women. CIMT was measured using B-mode ultrasound. Read More

View Article
June 2018
2 Reads

Editor's comment.

Authors:
Rodney J Baber

Climacteric 2018 Apr;21(2):197

a Clinical Professor of Obstetrics and Gynaecology , Sydney Medical School, The University of Sydney , Australia.

View Article
April 2018
2 Reads

Authors' reply.

Climacteric 2018 Apr;21(2):196

c Endocrine Research Center, Research Institute for Endocrine Sciences , Shahid Beheshti University of Medical Sciences , Tehran , I.R. Iran.

View Article
April 2018
2 Reads

Prediction of age at menopause in women with polycystic ovary syndrome: methodological issues.

Authors:
Siamak Sabour

Climacteric 2018 Apr;21(2):196

a Department of Clinical Epidemiology, School of Health , Shahid Beheshti University of Medical Sciences , Tehran , I.R. Iran.

View Article
April 2018
4 Reads

Surgical challenges in the treatment of perimenopausal and postmenopausal endometriosis.

Climacteric 2018 Aug 1;21(4):385-390. Epub 2018 Mar 1.

c Department of Obstetrics and Gynecology , Egemed Hospital , Aydin , Turkey.

Endometriosis is classically defined as a chronic, recurrent and progressive disease. It is known to be estrogen-dependent, but can still be observed during the peri- and postmenopausal periods. Medical management of endometriosis is palliative symptomatic relief. Read More

View Article
August 2018
2 Reads

The role of transvaginal ultrasound in screening for ovarian cancer.

Climacteric 2018 Jun 1;21(3):221-226. Epub 2018 Mar 1.

b Gynaecological Cancer Research Centre, Department of Women's Cancer, Institute for Women's Health , University College London , London , UK.

Ovarian cancer is a low-prevalence postmenopausal cancer with a high mortality rate and is the fifth most lethal cancer in women. The most common serous subtype with TP53 mutations spreads rapidly throughout the peritoneal cavity (stage III/IV) when 5-year survival is 10%. If diagnosed while confined to the ovary (stage I), the survival rate exceeds 90%. Read More

View Article
June 2018
2 Reads

Effects of oral contraceptives on ovulation induction in in vitro fertilization patients with premature ovarian insufficiency.

Climacteric 2018 Jun 28;21(3):276-279. Epub 2018 Feb 28.

a Navy Clinical Medical School , Anhui Medical University , Hefei , China.

Objective: To report a case series of in vitro fertilization patients with premature ovarian insufficiency, who were treated with oral contraceptives to reduce follicle stimulating hormone levels.

Method: This was a consecutive case series in a tertiary teaching hospital in China. Twenty-two women with refractory and idiopathic premature ovarian insufficiency were administered a drospirenone/ethinylestradiol oral contraceptive orally. Read More

View Article
June 2018
8 Reads

Innovative approaches to cervical cancer screening in low- and middle-income countries.

Climacteric 2018 Jun 28;21(3):235-238. Epub 2018 Feb 28.

a Sexual and Reproductive Health Unit , Papua New Guinea Institute of Medical Research , Goroka , Papua New Guinea.

The estimated cervical cancer burden is over ten-fold greater in low- and middle-income countries (LMICs) than in high-income countries. This health gap is thought to be primarily due to limited access to effective screening and treatment programs for cervical pre-cancer and cancer in such settings. The World Health Organization advocates a policy of 'screen and treat' approach to cervical screening in LMICs and subsequently visual inspection of the cervix with acetic acid (VIA) or Lugo's iodine (VILI), followed by ablative cervical cryotherapy if indicated, and this policy has been implemented in many high-burden settings. Read More

View Article
June 2018
2 Reads

Should women be screened for osteoporosis at midlife?

Authors:
T J de Villiers

Climacteric 2018 Jun 15;21(3):239-242. Epub 2018 Feb 15.

a Department of Gynecology, Faculty of Health Sciences , Stellenbosch University , Stellenbosch , South Africa.

Osteoporosis and associated fractures are common in women after midlife and will increase as the population ages. Osteoporosis-related fractures cause a significant increase in morbidity and mortality. Osteoporosis decreases the quality of life and productivity of many older women, with an increasing burden on health-care resources. Read More

View Article
June 2018
2 Reads

Role of breast density measurement in screening for breast cancer.

Authors:
K E McLean J Stone

Climacteric 2018 Jun 15;21(3):214-220. Epub 2018 Feb 15.

a Centre for Genetic Origins of Health and Disease , Curtin University and The University of Western Australia , Perth , WA , Australia.

Mammographic breast density is an established risk factor for breast cancer and significantly reduces the sensitivity of mammography, yet its use within breast cancer screening programs in Australia is limited. We provide a contemporary snapshot of the role of breast density measurement in screening for breast cancer and review the recent evidence for an increasing role of breast density measurement as: a predictor of breast cancer risk, a predictor of 'masking', and a biomarker to monitor effectiveness of intervention strategies for primary prevention or improved breast cancer outcomes. Read More

View Article
June 2018
2 Reads

Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause.

Climacteric 2018 Apr 13;21(2):148-152. Epub 2018 Feb 13.

c Department of Obstetrics and Gynecology , Catholic University of the Sacred Heart , Rome , Italy.

Objectives: To evaluate the long-term efficacy of a second generation of vaginal laser treatment, the vaginal erbium laser, as a non-ablative photothermal therapy for the management of genitourinary syndrome of menopause.

Methods: The study was performed using an erbium laser crystal yttrium-aluminum-garnet (XS Fotona Smooth™, Fotona, Ljubljana, Slovenia) with a wavelength of 2940 nm. Postmenopausal women (n = 205) were treated with three laser applications at 30-day intervals. Read More

View Article
April 2018
3 Reads

Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials.

Climacteric 2018 Apr 9;21(2):189-195. Epub 2018 Feb 9.

b Department of Pharmacy , Sun-Yat-Sen Memorial Hospital, Sun Yat-sen University , Guangzhou , PR China.

Aim: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the safety and efficacy of romosozumab in the treatment of postmenopausal osteoporosis.

Method: A comprehensive literature review was performed of PubMed, EMBASE, Cochrane Controlled Trials Registry, and Web of Science for RCTs. Outcome measures were changes in lumbar spine, total hip and femoral neck bone mineral density (BMD), incidence of fractures and adverse events. Read More

View Article
April 2018
5 Reads

Decision-making about mammographic screening: pursuing informed choice.

Climacteric 2018 Jun 8;21(3):209-213. Epub 2018 Feb 8.

a Wiser Healthcare, School of Public Health , The University of Sydney , Sydney , Australia.

For decades, persuasive techniques have been used to communicate to women about breast cancer screening with the aim of maximizing screening uptake. However, more recently this has shifted to an approach which recognizes that it is important for women to be aware of harms, such as overdiagnosis, as well as benefits of breast screening. There is a lack of consensus in the literature around whether benefits clearly outweigh harms for population-based breast cancer screening. Read More

View Article
June 2018
2 Reads

Traditional Chinese medicine: perspectives on and treatment of menopausal symptoms.

Authors:
Qi Yu

Climacteric 2018 Apr 8;21(2):93-95. Epub 2018 Feb 8.

View Article
April 2018
2 Reads

Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.

Climacteric 2018 Apr 7;21(2):167-173. Epub 2018 Feb 7.

g Departamento Médico , ITF Research Pharma S.L.U. , Madrid , Spain.

Objective: To determine the prevalence of genitourinary syndrome of menopause (GSM) and urogynecological conditions associated with menopause, and to evaluate the impact of GSM on quality of life in a cohort of Spanish postmenopausal women.

Methods: Multicenter, cross-sectional, and observational study involving 430 women.

Results: The prevalence of GSM was 70%. Read More

View Article
April 2018
5 Reads

Depressive symptoms affect outcomes of pessary use in postmenopausal women with uterine prolapse.

Climacteric 2018 Apr 3;21(2):184-188. Epub 2018 Feb 3.

a Department of Obstetrics and Gynecology , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing , PR China.

Objective: This study aimed to investigate the impact of depressive symptoms on successful pessary treatment for postmenopausal women with symptomatic pelvic organ prolapse (POP).

Methods: We performed a prospective study involving postmenopausal women with POP who visited our clinic seeking pessary treatment. Demographic information and medical histories were collected. Read More

View Article
April 2018
2 Reads

Vasomotor symptoms: natural history, physiology, and links with cardiovascular health.

Authors:
R C Thurston

Climacteric 2018 Apr 2;21(2):96-100. Epub 2018 Feb 2.

a Departments of Psychiatry, Psychology, and Epidemiology , University of Pittsburgh , Pittsburgh , PA , USA.

Vasomotor symptoms (VMS), or hot flushes and night sweats, are the classic symptom of menopause. Recent years have brought key advances in the knowledge about VMS. VMS last longer than previously thought, on average 7-10 years for frequent or moderate to severe VMS. Read More

View Article
April 2018
2 Reads

Association of body composition with menopausal symptoms in (peri-)menopausal women.

Climacteric 2018 Apr 2;21(2):179-183. Epub 2018 Feb 2.

a Department of Gynecology and Obstetrics , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , Shanghai , People's Republic of China.

Objective: To explore the correlation of body composition with the severity of menopausal symptoms, as well as each classic menopausal symptom.

Methods: A total of 758 (peri-)menopausal women were recruited (aged from 40 to 67 years) from the Menopause Clinic in the Shanghai Sixth People's Hospital. Different regions of fat mass, lean mass and fat-free mass were measured by bioelectrical impedance analysis, while menopausal symptoms were evaluated by valid modified Kupperman's index (KMI) in the Chinese version. Read More

View Article
April 2018
2 Reads